LeukoDx is an early-stage company advancing its novel compact fluorocytometry technology platform. The platform development was initiated at Caltech with NASA funding.
This groundbreaking technology has a wide range of applications, from early Sepsis detection, to HIV/AIDS monitoring and beyond.
It will deliver fast, actionable, sophisticated tests results at the point of care or in the field. This will help making better medical decisions when and where patient need them. It will also make test results accessible to a greater number of people than ever before.
The Bottom Line: Saving lives globally, with especially compelling results in the developing world.
LeukoDx was established by Cardio Ventures, a business accelerator dedicated to the development of medical device and diagnostics technology.
A Private Placement Memorandum for raising $1 million from private and angel investors is currently open. An intermediate first closing has already taken place. We anticipate product market launch within three years.
